AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01420471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone
Description: Spacer will be impregnated with 2mL of Triamcinolone. The triamcinolone-impregnated spacer will be inserted into the middle meatal space after surgery. The spacer will be left in the middle meatus for a period of 6 days following surgery.
Study NCT01420471 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saline-impregnated spacer
Description: Spacer will be impregnated with 2mL of Saline solution. The saline-impregnated spacer will be inserted into the middle meatal space intraoperatively. The spacer will be left in the middle meatus for a period of 6 days following surgery.
Study NCT03086382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide (LCM) tablet
Description: Treatment A: Single dose of Lacosamide (LCM) 200 mg given as 2 tablets of LCM 100 mg
Study NCT03086382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide (LCM) syrup
Description: Treatment B: Single dose of Lacosamide (LCM) 200 mg given as syrup
Study NCT03734315 — intervention group
Intervention type: DEVICE
Intervention: Ostenil®
Description: Ostenil® is a CE-certified viscoelastic solution for injection into the joint cavity, containing 1.0 % sodium hyaluronate from fermentation.
Study NCT01563835 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine, fentanyl
Description: 10mL of 0.125% of bupivacaine plus 50 mcg fentanyl, injected through an epidural catheter.
Study NCT01563835 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fentanyl
Description: fentanyl IV PCA with boluses 25-50 mcg, 3-6 minute lockout.
Study NCT00170664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Study NCT00170664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study NCT03437226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levosimendan 2.5 MG/ML
Description: Levosimendan Arm: 1 x 5 ml (1 vial) of levosimendan infusion concentrate is added to one 250 ml infusion bag of 5% glucose or 0.9% NaCl in diabetic patients.
Study NCT03437226 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo Arm: 1 x 5 ml (1 vial) of placebo levosimendan infusion concentrate is added to one 250 ml infusion bag of 5% glucose or 0.9% NaCl in diabetic patients.
Study NCT03543436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temocillin
Description: Intravenous temocillin disodium 2g intravenously/8h Or Renally Adjusted Equivalent (ORAE) in 30-40 min infusion or continuous intravenous (6g/24h) .
Study NCT03543436 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: meropenem or imipenem
Description: Intravenous carbapenem (meropenem 1g intravenously/8h Or Renally Adjusted Equivalent (ORAE) or imipenem 1g intravenously/8h ORAE)
Study NCT03460392 — intervention group
Intervention type: DRUG
Intervention: Antibiotic therapy
Description: To evaluate the effects of a specific event (i.e. surgical operation) or therapy (i.e antibiotic treatment) over time;
Study NCT03165838 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Postpartum Visit 3-4 Weeks
Description: This visit will be the same as the standard of care postpartum visit, but it will be scheduled earlier.
Study NCT03165838 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Postpartum Visit 6-8 Weeks
Description: This standard of care postpartum visit will be scheduled for the standard time interval.
Study NCT01026987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: Unrelated donors will receive only G-CSF (10 ug/Kg S/C qDay x5-6 days) prior to pheresis (collection of the stem cells). Unrelated donors will only be followed per NMDP guidelines.
Study NCT01026987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMD3100
Study NCT01026987 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Study NCT01026987 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Stem Cell Infusion
Study NCT03996135 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cannulation with AccuVein AV400
Description: Cannulation using AccuVein AV400 device
Study NCT02172235 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Study NCT02172235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Study NCT02172235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone - low dose
Study NCT02172235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773 - low dose
Study NCT02172235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773 - medium dose
Study NCT02172235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773 - high dose
Study NCT02598856 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intranasal (IN) naloxone 1x
Description: Administered as 100 μl 14.0 mg/ml (1.4 mg naloxone) by Aptar Unitdose device as one puff in one nostril
Study NCT00801723 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tablet
Description: Placebo Tablet once daily.
Study NCT04458441 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: warm group/cold group
Description: sequential randomization
Study NCT00987441 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine and sufentanil
Description: Ropivacaine 0.125% plus sufentanil 0.3 microgram
Study NCT00987441 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine and sufentanil
Description: Ropivacaine 0.125% plus sufentanil 0.4 microgram
Study NCT00987441 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine and sufentanil
Description: Ropivacaine 0.125% plus sufentanil 0.5 microgram
Study NCT00987441 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine and sufentanil
Description: Ropivacaine 0.0625% plus sufentanil 0.4 microgram
Study NCT00987441 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine and sufentanil
Description: Ropivacaine 0.1875% plus sufentanil 0.4 microgram
Study NCT00987441 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine and sufentanil
Description: Ropivacaine 0.25% plus sufentanil 0.4 microgram
Study NCT02085486 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard
Description: Standard inspection, palpation.
Study NCT02598856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal (IN) naloxone 1x
Description: Administered as 100 μl 14.0 mg/ml (1.4 mg naloxone) by Aptar Unitdose device as one puff in one nostril
Study NCT01675297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risedronate/Cholecalciferol combination
Description: Risendronate/Cholecalciferol combination once a week
Study NCT01675297 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risedronate
Description: Risedronate once a week
Study NCT01511614 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: Transcranial Direct Current Stimulation (tDCS), a type of Non-invasive Brain Stimulation (NIBS), has the potential to modify neuronal circuits by application of a subthreshold conductive current through the scalp. Two potential targets for tDCS as a smoking cessation aid are the dorsolateral pre-frontal cortex (dlPFC), a node of the ECN, and the ventromedial prefrontal cortex (vmPFC), a node of the DMN. tDCS can potentially strengthen the control of the ECN through excitatory stimulation of the dlPFC, and weaken the influence of the DMN (Lerman et al 2014) by inhibitory stimulation of the vmPFC. The tDCS model we will use is the neuroConn DC-Stimulator MR (neuroCare Group GmbH, Munchen, Germany).
Study NCT01511614 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham
Description: Sham Comparator
Study NCT02672150 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Core
Study NCT01511614 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Nicotine patch
Description: Dose-match Nicotine for non-deprived scan
Study NCT01511614 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo patch
Description: Nicotine deprived
Study NCT01511614 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Varenicline Pill
Description: Treatment
Study NCT01511614 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo pill
Description: Active comparator to varenicline
Study NCT01932970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etelcalcetide
Description: Etelcalcetide is provided as a sterile lyophilized powder to be reconstituted with sterile water for injection.
Study NCT02013700 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Adult Human Mesenchymal Stem Cells (hMSCs)
Study NCT02013700 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: matched placebo
Description: The placebo will be 25 ml of Plasma-Lyte A with 1% HSA in a Cryostore bag.
Study NCT02546531 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Defactinib
Study NCT02546531 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Study NCT02546531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Study NCT03053505 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: faecal human microbiota transplant (FMT)
Description: Non-randomized group R: Patients with recurrent CD infection are treated with FMT in this group.~Randomized group FFMT: patients with initial CD infection who have severe disease or who are at high risk of recurrence or high risk of developing severe disease are treated with FMT.
Study NCT03053505 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin or Fidaxomicin
Description: Randomized group FAB: patients with initial CD infection who have severe disease or who are at high risk of recurrence or high risk of developing severe disease are treated with antibiotics (vancomycin per os 125mg four times a day for 10 days) in this group. In case of treatment failure changes in antibiotic regime (e.g. fidaxomicin per os 200mg per two times a day for 10 days) will be allowed in the line with the recommendations of current CDI treatment guidelines(13).
Study NCT04389385 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 Specific T Cell derived exosomes (CSTC-Exo)
Description: The virus-specific T-cells (VSTs) are body's natural immune defense against various disease-causing viruses. Donor originated COVID-19 specific T-cells (CSTC) are in vitro activated and expanded by exposing to viral peptide fragments in the presence of natural immune stimulant proteins called cytokines. These Covid-19 specific fragment peptides activate specific T-cells and stimulate the secretion of potent mediators including IFN gamma in forms of exosomes. We propose treatment of Covid-19 patients -who are at early stages of pulmonary disease- with CSTC-exomes to control disease progression.
Study NCT02672150 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Core
Study NCT02672150 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced
Study NCT02590406 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Beach chair (BC) and ZEEP
Description: Table Position: Beach chair, Inclination of the upper part of the table at 25 degrees, breaking at the patient's hips ZEEP: 3 minutes pre-oxygenation with tidal volumes, FiO2 100%, mouth piece used as a ventilatory interface
Study NCT02590406 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reverse Trendelenburg and NIPPV
Description: Table Position: Reverse Trendelenburg, Inclination of the whole table at 25 degrees from an horizontal plane, head up.~NIPPV: 3 minutes of pre-oxygenation with 8 cm H2O positive pressure and 10 cm H2O PEEP. Trigger set at 1,5 L/min, mouth piece is used as a ventilatory interface
Study NCT03200028 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computerized Plasticity-Based Adaptive Cognitive Training
Description: Thirty minutes of training on computerized exercises that targets executive function, memory and attention.
Study NCT01376908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kuvan®
Description: Kuvan® (sapropterin dihydrochloride) tablets will be administered orally at the dose of 10 mg/kg/day and will be escalated to 20 mg/kg/day if after 4 weeks a subject's Phe tolerance is not increased by at least 20% versus baseline.
Study NCT01376908 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phenylalanine (Phe)-restricted diet
Description: Phe intake will be adjusted every 2 weeks, based on the mean Phe levels of the previous 2 weeks using pre-defined Phe adjustment criteria.
Study NCT01376908 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Phenylalanine (Phe)-restricted diet
Description: Phe intake will be adjusted every 2 weeks, based on the mean Phe levels of the previous 2 weeks using pre-defined Phe adjustment criteria.
Study NCT00563381 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium bromide
Description: 18 mcg/daily
Study NCT00563381 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol
Description: 100 mcg/daily
Study NCT00563381 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Salmeterol
Description: Placebo identical to Salmeterol device
Study NCT00563381 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Tiotropium
Description: Placebo identical to Tiotropium device
Study NCT01619774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2118436
Description: Starting dose 150 mg by mouth twice a day.
Study NCT01619774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1120212
Description: 2 mg by mouth daily.
Study NCT02688140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arsenic trioxide
Study NCT02688140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Study NCT02688140 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Idarubicin
Study NCT02688140 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Study NCT02688140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tretinoin
Study NCT02688140 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tretinoin
Study NCT02289833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab Emtansine
Description: Trastuzumab emtansine will be administered intravenously (IV) at a dose of 3.6 mg/kg on Day 1 of every 21-day cycle until disease progression (as assessed by the investigator), unmanageable toxicity, or study termination by the sponsor, whichever occurs first.
Study NCT02598856 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intranasal (IN) naloxone 2
Description: Administered as 2x 100 μl 14 mg/ml (2.8 mg naloxone) by Aptar Unitdose device as two puffs within the same nostril with 3 minutes interval
Study NCT02598856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal (IN) naloxone 2
Description: Administered as 2x 100 μl 14 mg/ml (2.8 mg naloxone) by Aptar Unitdose device as two puffs within the same nostril with 3 minutes interval
Study NCT01511614 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Motivational Interviewing
Description: Motivational Interviewing for smoking cessation preparation
Study NCT01436656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LGX818
Study NCT03403530 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IgM rich Immunoglobin
Description: the 'IgM rich immunoglobn' is the normal human immunoglobin containing Human plasma protein 50mg/ml of which immunoglobin is atleast 95% Immunoglobin M (IgM) 6mg Immunoglobin A (IgA) 6mg Immunoglobin G (IgG) 38mg
Study NCT03403530 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IgM rich Immunoglobin
Description: the 'IgM rich immunoglobn' is the normal human immunoglobin containing Human plasma protein 50mg/ml of which immunoglobin is atleast 95% Immunoglobin M (IgM) 6mg Immunoglobin A (IgA) 6mg Immunoglobin G (IgG) 38mg
Study NCT01573286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucagon-Like Peptide 2
Description: Patients will be treated with 20 ug/kg/day GLP-2, in two doses, given subcutaneously for 3 days (Phase 1). If the treatment is well tolerated, GLP-2 will be continued for a total of 42 days.
Study NCT01573286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucagon like peptide-2
Description: Patients will treated with 5, 10 or 20 ug/kg/day of GLP-2, given twice daily by subcutaneous injection. The initial cohort of patients will be treated at 5 ug/kg (n=6), and if this dose is seen to be safe, and levels appropriate, the next group of 6 will be treated at 10 ug/kg/day. If this dose is seen to be safe, and levels appropriate, the final group of 6 will be treated at 20 ug/kg/day.~Patients will be given GLP-2 at the assigned dose, subcutaneously for 3 days (Phase 1). If the treatment is well tolerated, GLP-2 will be continued, at the same dose, for a total of 42 days.
Study NCT02446028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIOD-531
Study NCT02446028 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humalog® Mix 75/25
Study NCT02180191 — intervention group
Intervention type: OTHER
Intervention: Comparison of the gut microbiota composition
Study NCT02557776 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Germline genetic testing of BRCA1 and BRCA2
Study NCT01934712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faster-acting insulin aspart
Description: Single dose injected subcutaneously (s.c, under the skin)
Study NCT01934712 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Faster-acting insulin aspart
Description: Single dose injected subcutaneously (s.c, under the skin)
Study NCT01934712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: Single dose injected subcutaneously (s.c, under the skin)
Study NCT01934712 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: Single dose injected subcutaneously (s.c, under the skin)
Study NCT01149005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: novorapid / humalog short acting insulin
Description: 1-4 units will be injected Subcutaneously (SC), before every main meal.
Study NCT01149005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Novo Rapid Insulin (Novonordisk)
Description: Novo Rapid Insulin (Novonordisk) will be administered before each main meal 1-4 units depends on the patients weight
Study NCT01926899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib administration
Study NCT02519478 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Helmetless Tackling Training (HuTT)
Description: see previous sections
Study NCT03697005 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BioHPP PEEK single posterior crowns
Description: BioHPP is a 20% ceramic reinforced, semicrystalline, thermoplastic and radiolucent polymeric material, used for fabrication of high strength fixed and removable prostheses. it has advantages of bio-compatibility, low density, light weight, shock absorption.
Study NCT03697005 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: zirconia-based single posterior crowns
Description: ZrO2, a ceramic material used for medical devices, displays good esthetic appearance, high mechanical strength, and high biocompatibility and is used in a wide range of indications, such as frameworks, implants, and abutments. In addition, it's very good long-term stability and reliability was proven in a 10-year clinical study. These excellent material properties and the transformation behavior are explained by the yttrium oxide stabilization of ZrO2.
Study NCT02598856 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous (IV) naloxone
Description: Administered as 1 ml Naloxon B Braun 0.4 mg/ml (0.4 mg naloxone), in an intravenous cannula in the opposite arm of which the blood samples are drawn from. IV bolus will be given rapidly (in less than 5 seconds)
Study NCT02598856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) naloxone
Description: Administered as 1 ml Naloxon B Braun 0.4 mg/ml (0.4 mg naloxone), in an intravenous cannula in the opposite arm of which the blood samples are drawn from. IV bolus will be given rapidly (in less than 5 seconds)
Study NCT02598856 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intramuscular (IM) naloxone
Description: Naloxone administered as 2 ml Naloxon B Braun 0.4 mg/ml (0.8 mg naloxone) in a Braun Omnifix 2.5 ml syringe using a BD Microlance 3 21G (green) 0.8x40 mm needle in the deltoid muscle of the non-dominant arm
Study NCT02598856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intramuscular (IM) naloxone
Description: Naloxone administered as 2 ml Naloxon B Braun 0.4 mg/ml (0.8 mg naloxone) in a Braun Omnifix 2.5 ml syringe using a BD Microlance 3 21G (green) 0.8x40 mm needle in the deltoid muscle of the non-dominant arm
Study NCT00676780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyphenon E (EGCG)
Description: 4 capsules daily with a meal for the duration of the study
Study NCT02688140 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitoxantrone